Top Markets
Coin of the day
Telo Genomics Corp. Telo Genomics Corp.

Telo Genomics Corp.

TELO
Rank in Stocks #35884
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on... Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health conditions. The company's primary innovation is a sophisticated telomere analysis platform, which serves both to diagnose diseases and to forecast patient outcomes. This technology, often integrated with liquid biopsies, provides crucial insights for applications in both cancer and neurological illnesses. Their leading product, Telo-MM, is specifically designed to arm medical professionals with vital, actionable information for effectively managing Multiple Myeloma, a serious blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software system capable of precisely measuring individual patient telomere characteristics. Telo Genomics caters to a broad spectrum of clients, including diagnostic pathologists, clinical doctors, academic researchers, and pharmaceutical developers. A notable endorsement of its technology is a collaborative agreement with the renowned Mayo Clinic, aimed at validating the Telo-MM diagnostic tests for multiple myeloma. Founded in 2014 and based in Toronto, Canada, the company adopted its current name, Telo Genomics Corp., in April 2019, having previously operated as 3D Signatures Inc.
Share Price
$0.03302716
Last synced: 2026-08-13
Market Cap
$3.32M
Change (1 day)
0.00%
Change (1 year)
-34.80%
Country
CA
Trade Telo Genomics Corp. (TELO)

Category

EPS for Telo Genomics Corp. (TELO)
EPS as of 2026 TTM: 0
According to Telo Genomics Corp. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Telo Genomics Corp. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors